SAN LUIS OBISPO, California - April 11, 2005 - FzioMed, Inc. announced today that it has been awarded a new United States patent covering the company's Oxiplex® technology. Oxiplex is a versatile polymer biomaterial developed by FzioMed for use in a wide variety of surgical specialties.

The new patent, US 6,869,938, covers compositions of polyacids and polyethers, and methods for their use in reducing postsurgical adhesions.

"Our Oxiplex synthetic technology represents the next generation in biomaterials," said Richard Berg, Ph.D., Vice President of Research and Development for FzioMed, Inc. "We're pleased to receive another patent that deepens coverage for our pipeline of Oxiplex-based products."

FzioMed is a privately held medical company engaged in the development and commercialization of synthetic, absorbable biomaterials based on the company's patented Oxiplex technology. FzioMed is developing products for the prevention of postsurgical adhesions, tissue augmentation and regeneration, and the delivery of drugs. Oxiplex is an innovative polymer technology with potential uses across a wide variety of specialties including orthopedics, gynecology, general surgery, cardiac, neurosurgery and aesthetic surgery. FzioMed products include Oxiplex/SP Gel, the leading adhesion barrier for spine surgery, currently marketed outside of the United States. Other FzioMed products are in various stages of development and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery materials.

FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.

Back to News Articles